
ACXP Stock Forecast & Price Target
ACXP Analyst Ratings
Bulls say
Acurx Pharmaceuticals Inc is well-positioned for growth due to positive feedback from both the FDA and EMA regarding its antibiotic candidate, ibezapolstat (IBZ), ahead of the critical Phase 3 trial in adult populations. The company has also demonstrated encouraging antimicrobial activity coupled with a favorable safety profile for IBZ, further enhancing its potential marketability. Additionally, the recent positive opinion from the Pediatric Committee of the EMA on the company's Pediatric Investigation Plan for IBZ indicates broader applicability and regulatory support for the drug's use in children, strengthening the overall outlook for Acurx Pharmaceuticals.
Bears say
Acurx Pharmaceuticals Inc. faces significant challenges due to its clinical stage status, which inherently carries high development risks and uncertainty surrounding successful regulatory approval for its antibiotic candidates. The company is operating in a highly competitive biopharmaceutical sector, where the reliance on government and health organizations for prioritizing its target infections may not guarantee market adoption or profitability. Additionally, the financial metrics are concerning, as the company's limited revenue generation combined with high operational costs and reliance on funding may impede its ability to sustain long-term growth and stability.
This aggregate rating is based on analysts' research of Acurx Pharmaceuticals LLC and is not a guaranteed prediction by Public.com or investment advice.
ACXP Analyst Forecast & Price Prediction
Start investing in ACXP
Order type
Buy in
Order amount
Est. shares
0 shares